Posts

Apnimed Targets Up to $160M IPO for Sleep Apnea Drug Oxnimbi Launch

on

Biogen's Tau-Targeting Alzheimer's Drug Shows Promising but Confusing Results

on

Tenpoint Therapeutics Submits MAA for YUVEZZI to MHRA for Presbyopia Treatment in Adults

on

Friday Five: FDA steps up to counter China’s clinical‑trial edge, AbbVie buys Apogee, and psychedelics hype yields real data

on

Roche's Fenebrutinib Delays MS Relapses in Phase 3 Trials but Faces Liver Toxicity and Safety Scrutiny

on

Biogen Acquires Exclusive Rights to Felzartamab in Greater China Region from TJ Biopharma

on

Trevi Therapeutics Raises $150M in Public Offering to Fund Haduvio Development

on

GSK Advances B7-H4 ADC Mocertatug Rezetecan to Five Phase 3 Trials After Strong Phase 1b Data in Gynecological Cancers

on

Merck Touts Strong Comparator Data for Enlicitide Decanoate, Oral PCSK9 Inhibitor Reducing LDL-C by Up to 60% in Phase 3 Trials

on

Sanofi's Venglustat Scores Phase 3 Win in Gaucher Disease, Misses in Fabry Disease

on

Alumis' TYK2 Inhibitor Envudeucitinib Succeeds in Phase 3 Psoriasis Trials, Plans FDA Filing

on

Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219

on

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

on

Merck & Co.'s Welireg Notches Wins in Kidney Cancer Combo Studies

on

Forging the Future of Cell Therapy: Bayer and BlueRock's Unique Journey

on

Forging the Future of Cell Therapy: Bayer and BlueRock's Unique Journey

on

Incyte's oral HS drug hits study goals, but fails to excite investors

on

Merck's HIV Combo Treatment Advances Towards FDA Filing

on

Biogen Secures $250 Million R&D Funding from Royalty Pharma for Lupus Drug Litifilimab

on

Royalty Pharma Invests $250M in Biogen's Late-Stage Lupus Treatment

on